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Abstract
Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-5% of
patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and mutations in
FGFR genes have been identified in patients with NSCLC and clinical trials are testing the
efficacy of anti-FGFR therapies. FGFR2 and other FGFR kinase family gene alterations have
been found in both lung squamous cell carcinoma and lung adenocarcinoma though mouse models
of FGFR driven lung cancers have not been reported. Here, we generated a genetically engineered
mouse model (GEMM) of NSCLC driven by a kinase domain mutation in FGFR2. Combined with
p53 ablation, primary grade III/IV adenocarcinoma was induced in the lung epithelial
compartment exhibiting locally invasive and pleiotropic tendencies largely made up of
multinucleated cells. Tumors were acutely sensitive to pan-FGFR inhibition. This is the first
FGFR2-driven lung cancer GEMM, which can be applied across different cancer indications in a
preclinical setting.
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Introduction
Non-small cell lung cancer (NSCLC) currently remains the leading cause of cancer-related
deaths worldwide; over 200,000 new cases are diagnosed annually, of which only 16% of
patients survive longer than 5 years (1) NSCLC represents the most common subtype of
lung cancer and is comprised of large cell, squamous cell and adenocarcinomas (2), all of
which are being intensely researched to further delineate their respective oncogenic drivers
and therapeutic targets. In turn, there is significant pre-clinical need for the development of
novel genetically engineered mouse models (GEMMs) that exploit these potential ‘drivers’
to further understand their underlying biology and relevance as therapeutic biomarkers.
Upon successful recapitulation of the human disease in the mouse, researchers are able to
test novel targeted therapeutics in order to improve therapies for specific patient genotypes
in NSCLC.
Fibroblast growth factors (FGFs) and their cognate cell surface receptors comprise a large
signaling network, playing key roles in embryonic development and normal tissue
homeostasis via ligand binding of the extracellular domains in fibroblast growth factor
receptors (FGFRs). Aberrant activation of these receptor tyrosine kinases (RTKs) has been
demonstrated in a variety of cancer types. To date, FGFR1 amplification and gene
expression has been the most commonly discovered, identified in 10% of breast carcinomas
(3), approximately 20% of squamous cell lung cancers (4, 5), and 6% of small cell lung
cancer patients (6). FGFR2 mutations have been most highly represented in 12% of
endometrial carcinoma patients (7), both major subtypes of NSCLC with the squamous cell
population displaying a higher rate of mutation (8–10) and gastric tumors (11), as well.
Somatic mutations in FGFR3 have been most commonly observed in bladder carcinomas
(12) and a serine to cysteine amino acid change at amino acid 249 has been identified in 5%
of invasive cervical carcinomas (13). Similar to the case of EML4-ALK, activating
chromosomal translocations of FGFRs have begun to be identified in several different
cancer types, including bladder cancer (14), multiple myeloma (15), lung squamous cell,
thyroid, oral, head and neck squamous, breast and prostate cancers as well as
cholangiocarcinoma and glioblastoma. (16) FGFR2/3/4 mutations were also identified in
NSCLC (8, 9) providing the rationale for the creation of GEMMs driven by FGFR-
dependent activity.
To date, several mouse models of lung tumorigenesis have been generated which are driven
by different FGF7 subfamily members (FGF3/7/10). Each of these mouse models exhibited
epithelial hyperplasia with some providing adenomas, but none of these models rendered an
invasive cancer phenotype (17–19). More recently, a group described an inducible mouse
model driven by FGF9 expression in the adult mouse lung. (20) This model was the first to
develop papillary adenomas, which progressed to adenocarcinoma with the potential to
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metastasize and was dependent on a FGF9-FGFR3 signaling axis. Given that FGF3/7/10
ligands predominantly signal through FGFR2 (21), the pre-clinical need for additional
FGFR-driven models of invasive carcinoma is needed, as mutations in all FGFRs have been
identified in various next generation sequencing efforts in various cancer indications,
including NSCLC. (8, 9) Additionally, modes of resistance to tyrosine kinase inhibitors
related to FGFR de-repression is also of interest. While there have been many FGFR
mutations identified in NSCLC, limited knowledge as to which are oncogenic drivers
continues to be an obstacle. As a result of data generated by TCGA analysis of lung
squamous cell and adenocarcinoma, several potentially key ‘drivers’ were uncovered. Of
those, FGFR2 was of particular interest as it is commonly mutated and/or amplified in both
lung squamous cell and adenocarcinoma patients. (8, 9) Upon further evaluation of FGFR2,
several key mutations in both the extracellular and kinase domains showed transforming
capabilities in vitro and in xenograft studies with profound sensitivity to pan-FGFR
inhibitors, such as BGJ-398 and AZD4547. (22) Based on these findings and the clear void
of mouse models of human lung squamous cell carcinoma, here we report the generation and
characterization of FGFR2 mutant GEMMs conditionally expressing an extracellular
(W290C) or kinase (K660N) domain activating mutation.
Methods
Generation and maintenance of transgenic mice
Point mutations W290C and K660N within human FGFR2’s cDNA (isoform IIIb) were
introduced as described elsewhere. (22) In short, sequence-verified constructs were cloned
into a modified transgenic targeting vector. (23) Sequence-verified targeting vectors were
co-electroporated with an FLPe recombinase plasmid into v6.5 C57BL/6J (Female)×129/sv
(Male) embryonic stem (ES) cells (Open Biosystems) as described elsewhere. (24) Resulting
hygromycin-resistant ES clones were evaluated for transgene integration via PCR. Then,
transgene positive ES clones were injected into black 6 blastocysts and resulting chimeras
were mated with BALB/c WT mice to determine germline transmission of the FGFR2
transgene. FGFR2 transgenic mice were bred with a p53 conditional knockout (Trp53flox/flox
– Jackson Laboratories #8462) model. For all studies, mice were on a mixed genetic
background and FGFR2 mutant mice were hemizygosed. Adenovirus-Cre (5x107 pfu –
University of Iowa) was administered intranasally to excise the loxP sites, activating mutant
FGFR2 expression and inactivating p53 activity in the lung epithelial compartment. All
mouse experiments were performed with the approval of the institutional animal care and
use committee at Dana-Farber Cancer Institute.
Mouse drug treatment studies
Upon signs of dyspnea, mice were imaged via magnetic resonance imaging (MRI) to
document baseline tumor volumes. BGJ-398 (SelleckBio #S2183) was dosed orally 7 days/
week (15mg/kg in PEG300). (22, 25) Vehicle animals were treated with PEG300 alone
(EMD). MRI was performed at 1, 2 and 4 weeks throughout treatment. Tumor volumes were
quantified using 3D Slicer software as described elsewhere. (26)
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Real time PCRs
Total RNA was isolated from lung tissues/nodules using Trizol (Invitrogen #15596018) and
processed thru a RNA cleanup step (Qiagen #74204) per manufacturers’ instructions.
cDNAs were generated from resulting total RNA samples via the high-capacity RNA-cDNA
kit (Invitrogen #437;7474). Real time assays were performed with real time human FGFR2
(F: GATAAATACTTCCAATGCAGAAGTGCT R:
TGCCCTATATAATTGGAGACCTTACA) or mouse GAPDH (F:
CATGGCCTTCCGTGTTCCTA R: CCTGCTTCACCACCTTCTTGAT) primers using the
Syber Green kit (Invitrogen #4364344) using 80 ng cDNA per manufacturer’s instruction.
Triplicates were evaluated for each sample. The ΔΔCT method was used to quantify relative
mRNA quantities. Data is displayed in fold changes as compared to internal control mouse
GAPDH.
Western Blotting and antibodies
Tumor tissues were mechanically homogenized in RIPA buffer with EDTA (Boston
BioProducts) with a protease/phosphatase inhibitor cocktail (Thermo Scientific). 25 µg of
total protein was separated by SDS-polyacrylamide gel electrophoresis (Invitrogen) and
transferred to PVDF (Millipore). Immunoblots were probed for various proteins, including
FGFR2 (C8, Santa Cruz #6930), total-FRS2a (Abcam #10425), phospho-FRS2a (Cell Sig.
#3861), total-Erk1/2 (Cell Sig. #4695), phospho-Erk1/2 (Cell Sig. #4370), total-Akt (Cell
Sig. #9272), phosphor-Akt (Cell Sig. #4060), and beta-actin (Cell Sig. #4967).
Immunohistochemistry and antibodies
Mouse lungs were inflated and fixed with 10% buffered formalin overnight and embedded
in paraffin (FFPE). Unstained sections were stained with the following antibodies: TTF-1
(Epitomics, #58803-1), SFTPC (Chemicon, #AB378), CC-10 (Santa Cruz, #sc-9772),
FGFR2 (Atlas Antibodies #HPA035305), phospho-FRS2a (Abcam #78195), and phospho-
Akt/Erk1/2 (see above). Staining kits for Ki67 (Vector #VP-K451) and TUNEL (Millipore
#S7100) were performed per manufacturer’s instructions. Three representative images were
quantified per mouse and averaged with a minimum sample size of 6 animals per cohort
(treated vs. untreated).
Statistics
P-values for all survival curves were assessed by log-rank test while all other p-values were
assessed by Student’s T-test (GraphPad Prism).
Results
Next generation sequencing (NGS) of patient samples has been increasingly performed in
order to uncover their oncogenic drivers and determine whether or not targeted therapy
would be potentially more beneficial over cytotoxic therapy. We interrogated three
publically available NSCLC datasets for mutation in FGFR2 (Supplemental Table 1) (8, 9,
27). Mutations in FGFR2 are spread across the gene, primarily focused in the extracellular
or kinase domains, in NSCLC (Figure 1A). Mutations in these domains have been
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previously shown to lead to constitutive receptor dimerization or kinase activity,
respectively, driving oncogenic intracellular signaling. (22)
Patients with FGFR2 mutations ranged in age from 42 to 81, averaging 66 years of age upon
diagnosis. The combined data also suggested the 2:1 ratio of tumor histology (squamous cell
carcinoma to adenocarcinoma) with no predilection for light to non-smokers. Due to an
overwhelming need for mouse models of novel oncogenic drivers in lung cancer, we set out
to evaluate newly characterized FGFR2 mutations which were established to be
transforming and oncogenic in vitro and in vivo. (22)
We generated inducible models of human FGFR2-IIIb mutations found in the extracellular
(W290C) or kinase domains (K660N) (Supplemental Figure 1). Patients with previously
reported FGFR2 mutations were largely devoid of intact p53 activity (>85%), (9) therefore,
the FGFR2 GEMMs were crossed with the Trp53fl/fl model to obtain a bi-allelic mouse
(Figure 1B). The gain or loss of function of FGFR2 or p53, respectively, was conditional via
cre-lox technology. At 6 weeks of age, bi-allelic mice were induced via intranasal delivery
of adenovirus-cre (5×107 pfu), activating mutant FGFR2 activity while inactivating p53.
Induced animals revealed a lung tumor latency of 28 to 32 weeks post adenovirus-cre
administration (Figure 1B). Sick animals presented with progressive dyspnea and weight
loss. As expected, bi-allelic FGFR2K660N;p53−/− tumor bearing animals displayed a
significant decrease in overall survival as compared to un-induced littermate controls
(Figure 1C). Resulting tumors resembled poorly differentiated human grade III/IV lung
adenocarcinoma displaying high pleiotropy and heavily multi-nucleated tumor cells
exhibiting strong characteristics of local invasion throughout the lung parenchyma (Figure
1D). Indeed, these tumors expressed robust levels of the adenocarcinoma marker, thyroid
transcription factor 1 (TTF-1) (Figure 1E). To further characterize the model, tumors were
stained with surfactant protein C (SFTPC – Figure 1E) suggesting a type II pneumocyte
differentiation, similarly observed in another mouse model of lung adenocarcinoma driven
by FGF9. (20) These tumors stained negative for the clara cell antigen (CC10) marker at
both early and late time points (20 and 32 weeks post-induction), while the clara cells of the
alveolar epithelium stained positive (Supplemental Figure 2). FGFR2 mutant models
displayed similar phenotypes, but the penetrance for the extracellular domain (ECD) was
less than the kinase domain (KD), 35% versus 92%, respectively. Furthermore, the ECD
(W290C) model’s tumor latency was substantially longer than that of the K660N (KD)
animals. Thus, we chose to move forward with the kinase domain mutant for treatment
studies because of its increased oncogenic activity (22) and recurrent mutation in patient
samples (Supplemental Table 1). Loss of p53 activity yielded increased penetrance (40% vs.
92% for p53 wt and null, respectively) and decreased tumor latency (Supplemental Table 2).
Mutant mice developed distinct macroscopic nodules (Supplemental Figure 3) that provided
for isolation from normal adjacent lung in order to molecularly characterize them, both at
the RNA and protein level. Human FGFR2 mRNA in tumor nodules was 15-20 fold higher
than what was found in normal un-induced lung (Figure 2A). In general, FGF receptors
signal through a key intracellular binding partner, fibroblast growth factor receptor substrate
2 alpha (FRS2α) that leads to MAPK and PI3K/Akt activity. (28) As a result of FGFR2
over-expression in our GEMM, elevated phosphorylation events in FRS2α demonstrated the
Tchaicha et al. Page 5
Cancer Res. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
receptors increased tyrosine kinase activity, leading to increased levels of phosphorylated
AKT and ERK1/2 (Figure 2B).
Next, we validated our immunoblot results via immunohistochemistry for the same
downstream signaling mediators resulting from increased FGFR2 activity (Figure 2C &
Supplemental Figure 4). Tumor nodules from both mutant FGFR2 models displayed robust
specific cell surface staining of FGFR2. A tumor driven by mutant Kras activity showed no
staining (Supplemental Figure 5A). Expected phosphorylation of various downstream
signaling molecules, including AKT, ERK1/2 and FRS2α were present in tumor nodules
from both the kinase domain mutant (Figure 2C) and the extracellular domain mutant
(Supplemental Figure 4). Both models were deemed proliferative and actively growing as a
result of positive Ki-67 immunohistochemistry.
Until relatively recently, the standard of care for advanced NSCLC patients has been limited
to cytotoxic chemotherapy when surgery and radiotherapy were otherwise ineffective. (29)
With the boom of targeted therapy driving patient sub-stratification, we wanted to evaluate
the effect of a pan FGFR inhibitor in our FGFR2 driven lung cancer model. In a tumor
efficacy study, we treated FGFR2K660N;p53−/− lung tumor bearing animals with either
BGJ-398 (n=10), a pan FGFR inhibitor or vehicle (n=5). Tumors were confirmed via MRI
and served as baseline tumor volume. After one week of treatment with daily, orally
delivered 15mg/kg BGJ-398, eight of ten animals displayed greater than 50% tumor
regression and three of ten animals had regressed 80% (Figure 3A, B). This phenomenon is
very similar to the efficacy of erlotinib in our mutant EGFR-driven lung cancer mouse
model. (30) Efficacy of BGJ-398 continued to significantly improve at 2 and 4 weeks as
compared to vehicle treated animals (Figure 3C), where animals showed near remission with
eight of ten animals showing greater than 75% tumor regression (Supplemental Figure 5B).
Long-term sustained tumor remission is being evaluated with no acquired resistance seen at
6 months (n=4) (data not shown).
Next, we investigated the changes in downstream signaling pathways as a result of BGJ-398
treatment. Lung tumor bearing mice were treated for two days with either vehicle or
BGJ-398 (15 mg/kg) and sacrificed 2 hours after the second dose to evaluate the drug’s
pharmacodynamics. Isolated tumor nodules from both vehicle and drug treatment arms were
evaluated for phosphorylated FRS2α, AKT and ERK proteins. (31) Overall, inhibition of
FGFR2-dependent tyrosine kinase activity reduced MAPK and PI3K signaling (Figure 4A)
with obvious phosphorylation depletion in key signaling proteins FRS2α, AKT and ERK1/2.
As a result of short term dosing, BGJ-398 treated tumors displayed signs of decreased
proliferation (Ki-67) and increased apoptosis (TUNEL) via immunohistochemistry (Figure
4B). Moreover, there was a significant overall survival benefit of animals undergoing
BGJ-398 treatment (n=12) compared to an untreated, induced group (n=30) (Figure 4C).
Animals died on treatment due to issues unrelated to lung tumor or drug toxicity, most
commonly due to improper oral dosing (n=2) or a secondary tumor arising in the nasal
airway epithelia that commonly metastasized to the brain (Supplemental Figure 6). Unlike
the tumors originating in the lungs, these FGFR2 positive nasal tumors were negative for the
type II pneumocyte marker SFTPC (Supplemental Figure 6). After review, a Veterinary
Pathologist termed these esthesioneuroblastomas (n=2, Supplemental Figure 6), arising from
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the neuroepithelium. These tumors developed well beyond the normal lung tumor latency (>
50 weeks), likely as a direct result of nasally delivered adenovirus cre and resulted in
lethality due to obstruction of the nasal cavity, affecting the animal’s normal respiration.
BGJ-398 caused a significant decrease in proliferation (Figure 4D) and a significant increase
in apoptosis of the lung tumor cells (Figure 4E) after a short-term (2 day) treatment resulting
in near complete tumor regression at four weeks.
Discussion
FGF ligands and their cognate receptors have become significant clinical targets of interest
in the oncology field. Recently, a group reported an inducible mouse model driving FGF9
expression in the adult airway epithelia leading to the formation of papillary adenomas,
which were shown to progress into primary adenocarcinomas with a metastatic potential.
(20) The FGF9 expression signaled through the FGFR3 receptor and once the tumors were
established, they were shown to be FGF9-independent. Furthermore, while widespread
expression of FGF3 and FGF7 in the adult mouse lung was shown to produce type II cell
hyperplasia (18, 19), FGF9 or FGF10 expression led to the development of cancer or
adenomas, respectively. (17, 20) Interestingly, the FGF7 subfamily of ligands (FGF3, 7, 10)
is known to preferentially bind FGFR2 receptors, while FGF9 has been shown to signal
through FGFR3 (21) suggesting both receptors are important in lung tumor development.
Activating mutations in FGFR2 have recently been unveiled as novel targets in NSCLC,
both in lung squamous cell and adenocarcinoma. (8, 9) Inherent in their clinical relevance,
models driven by FGFR2 activating mutations have the potential to help researchers explore
the biology of the receptor tyrosine kinase and to evaluate novel targeted therapies for
patients that fall into this genetically defined subset of cancers. A multitude of FGFR2
mutations have been identified in NSCLC, although it has been unclear as to which are, in
fact, oncogenic drivers up until recently. (22) In addition, with the recent success of targeted
therapies in lung adenocarcinoma patients, it would be advantageous to develop novel
models of FGFR-driven lung squamous cell carcinoma (SqCC) given the prevalence of
FGFR alterations in this disease.
Described herein, we have developed the first FGFR2-driven genetically engineered mouse
model (GEMM) of NSCLC. We developed conditional bi-allelic mice that upon exposure to
nasally delivered adenovirus-cre led to activated FGFR2 signaling, while also abrogating
p53 function concurrently. Both mutant models that were developed yielded primary grade
III/IV lung adenocarcinoma that led to a significant decrease in overall survival as compared
to un-induced control littermates. While p53 loss of function was not required for tumor
formation (Supplemental Table 2), it was necessary to provide reasonable tumor latency for
long-term efficacy studies to be completed. Combining loss of p53 with constitutive FGFR2
signaling led to a marked reduction in tumor latency, also observed in a KRAS driven
mouse model of lung cancer. (32) Furthermore, combining loss of p53 in our model is
clinically relevant given the high frequency of p53 loss in lung cancers. (8, 9)
Unlike the FGF9 model where the oncogene is broadly expressed in all cells expressing
SFTPC throughout the lung, our system targets a smaller number of epithelial cells of
Tchaicha et al. Page 7
Cancer Res. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
diverse lineages via expression of Cre recombinase by nasal inhalation of adenovirus. This
difference in technique may explain the shorter latency in previously described models. (17,
20) Differences in latency are possibly also due to overexpression of FGF ligands in
previous models versus expression of the mutant receptor in this model. Ligands can have
non-cell autonomous effects on the other cells in the tumor microenvironment such as
endothelial cells (33) or cancer associated fibroblasts (34, 35), likely supporting the growth
of these tumors. In contrast to the previously described FGF9 model, early or late lesions in
our FGFR2 model lack CC-10 staining, potentially indicating a non clara cell origin though
additional work is required to discover the cell of origin in these tumors (Supplemental
Figure 2).
This FGFR2-driven GEMM of NSCLC was created to study the development and clinical
aspects of lung cancer; however previously established mouse models overexpressing
different FGFs in the lung show similar but also distinct phenotypes to the current model.
The proliferative phenotypes in the FGF7 subfamily models are dependent on sustained FGF
signaling (17–19) while the FGF9 model develops ligand independence upon tumor
formation via FGFR3 signaling. (20)
As expected, lung tumors driven via constitutive FGFR2 signaling displayed increased AKT
and ERK activity correlating with FRS2α phosphorylation. As the extracellular domain
model had longer tumor latency, we chose to test BGJ-398, a pan-FGFR inhibitor, in our
kinase mutant model. This model displayed exquisite sensitivity to BGJ-398 just after one
week of dosing. By four weeks after dose commencement, a large majority of tumor bearing
animals had undergone nearly full tumor remission lending to significantly longer overall
survival compared to untreated lung tumor bearing animals. This sustained response was
durable and strikingly resembled our study of EGFR tyrosine kinase inhibitors in mutant
EGFR-driven mouse lung cancers. (30) There was a small group of BGJ-treated animals that
died of improper oral dosing or tumors arising in the nasal epithelia. The animals showing
near complete lung tumor remission developed SFTPC negative nasal tumors that protruded
into the brain while also impeding upon the animal’s breathing capacity. The lack of type II
alveolar marker staining (SFTPC) in these tumors confirms that they are not a result of lung
metastasis. We have adapted an intratracheal delivery method to circumvent this issue in the
future. While we cannot unequivocally suggest why the BGJ-398 had no therapeutic effect
on these tumors, a proper drug pharmacokinetic and pharmacodynamic study would be
beneficial to assess the drugs capability to penetrate the blood brain barrier.
Although the mutations in FGFR2 were identified in an SqCC patient population, elevated
FGFR2-related activity is seen across both major subtypes of NSCLC. While we set out to
develop a mouse model that recapitulates human FGFR2-driven NSCLC, we were not
surprised by the adenocarcinoma phenotype as the pre-clinical space is largely devoid of a
lung SqCC mouse model for many potential reasons. First, when inducing oncogene
expression in the mouse lung, targeting is largely directed to type II pneumocytes (alveolar
type II cells), which have a predilection to lead to bronchio-alveolar adenomas leading to
lung adenocarcinoma. (36) Furthermore, the naïve mouse lung epithelium has no squamous
cell differentiation until an inflammatory event occurs driving metaplasia, which is often
initiated in SqCC patients by smoking. (37) Recently, a group has shown the necessity for
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chronic inflammation to drive spontaneous SqCC formation within the mouse lung. They
reported inactivation of IKKα (kinase-dead IKKα knock-in) drives the up-regulation of
SqCC-associated markers including p63, Trim29 and keratin 5 leading to down-regulation
of LKB1 (STK11) activity. (38) Second, there are likely several features of the
microenvironment that are playing roles in squamous cell differentiation which a transgenic
environment would have difficulty recapitulating without that initial inflammatory insult.
Third, there is also a strong possibility that those patients with FGFR2 mutations may
require another collaborating oncogene to drive the differentiation into the squamous cell
histology, or perhaps the loss of another tumor suppressor.
In summary, we have developed a mouse model of lung adenocarcinoma driven by FGFR2
constitutive kinase activation originally identified in NSCLC patients. With the exquisite
sensitivity of the lung tumor model to a pan-FGFR inhibitor, researchers gain a powerful
tool to further bolster their understanding of FGFR-related cancer biology and targeted
therapy discovery within the lung and across various cancer indications. In addition, with the
inevitability of acquired resistance, this model could be of significant value for evaluation of
response to targeted therapies, chemotherapy as well as novel immunotherapies in an
immune-competent environment. Together, these data validate a role for FGFR2 in lung
adenocarcinoma providing a model to further make an impact in the decisions made by an
oncologist treating this genetically defined population in the clinic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Kinase domain activation of FGFR2 drives the formation of grade III/IV lung
adenocarcinoma in a GEMM of NSCLC
(A) Recurrent FGFR2 mutations observed in lung adenocarcinoma and squamous cell
carcinoma patient primary tumor biopsies. (B) A GEMM conditionally expressing human
FGFR2K660N was crossed (two generations) with a conditional p53 inactivating GEMM to
obtain a FGFR2K660N;p53fl/fl mouse. Compound conditional mutant animals were induced
at 6 weeks of age via nasally delivered adenovirus-cre. Tumor latency ranged from 28-32
weeks post-induction. (C) FGFR2 kinase domain mutation (n=30) significantly (p<0.0001)
reduced the overall survival of animals as compared to un-induced littermate controls
(n=20). (D) Two representative H&E images of poorly differentiated lung adenocarcinoma.
Note the upper panel represents grade III lung adenocarcinoma displaying pleomorphic
nuclei (arrows) and the lower panel represents grade IV lung adenocarcinoma exhibiting
tumor cells invading towards the blood vessel (asterisks) (left/right panel magnification bars
= 100 µM and 50 µM, respectively). (E) Tumors exhibited robust expression of TTF-1, a
marker for adenocarcinoma as well as surfactant protein C (SFTPC). Adjacent non-
malignant regions display basal levels of both markers (magnification bars = 50 µM).
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Figure 2. Conditional activation of FGFR2K660N and inactivation of p53 in the lung
compartment drives expression of FGFR2 and its intracellular signaling counterparts
(A) 15-20 fold higher FGFR2 mRNA levels were observed in tumors driven by conditional
activation of the bi-allelic GEMM as compared to normal lung controls (normalized to
mouse GAPDH). (B) Expression of FGFR2, FRS2, pFRS2 (Y436), AKT, pAKT (S473),
ERK, and pERK1/2 (T202/Y204) by western blot. Tumor nodules from four different mice
and a control mouse lung are shown. β-actin was run as a loading control. (C)
Representative images from H&E staining and immunohistochemistry for Ki-67, FGFR2,
and phosphorylated forms of FRS2α, AKT, and ERK on FFPE sections of the same tumor
nodule shown at low and high magnifications (inset image scale bar = 100uM, high
magnification scale bar = 50uM).
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Figure 3. Pan-FGFR inhibitor, BGJ-398, is effective against FGFR2-driven lung
adenocarcinoma in a genetically engineered mouse model
(A) Representative serial MR images of two FGFR2K660N;p53−/− lung tumor bearing mice
treated once daily for four weeks with either BGJ-398 (15 mg/kg) or vehicle (PEG300).
Images represent baseline, one, two and four weeks after start of treatment (White ‘H’
indicates the heart). (B) Quantification of tumor burden from the MR images in BGJ-398
(upper waterfall plot) or vehicle (lower waterfall plot) treated mice at 1, 2, and 4 weeks after
the start of treatment. (C) Comparison of tumor volume changes in BGJ-398 or vehicle
treated mice at 4 weeks after the start of treatment (p<0.0001) (n=10 and 4 respectively).
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Figure 4. BGJ-398 increases the survival benefit via abrogation of key intracellular signaling
cascades leading to decreased proliferation and increased cell death
(A) Western blot analysis showing pharmacodynamic markers of the canonical FGFR
signaling pathway; phosphorylated protein levels of AKT (S473), ERK (T202, Y204), and
FRS2α (Y436) in BGJ-398 or vehicle treated mouse lung tumor nodules. Respective total
proteins and β-actin westerns were also performed as loading controls. Each lane represents
a tumor nodule from a different mouse. (B) Representative images of Ki-67, pFRS2 and
TUNEL IHC staining on FFPE slides of tumor nodules from mice treated for three days
either with BGJ-398 or vehicle (scale bar = 50µM). (C) BGJ-398 treated (n=12) lung tumor
bearing animals survive significantly (p<0.0001) longer than untreated, induced lung tumor
bearing animals (n=30) with some (n=4) succumbing to non-tumor related deaths (see
results). Mean Ki-67 (D) or TUNEL (E) positive cells per 20X field (n=3/mouse) show a
significant decrease in proliferation (p=0.0032) and significant increase in apoptosis
(p=0.0138) in the BGJ-398 treated cohort. [Ki-67 study – n=8/6 (vehicle/BGJ-398) and
TUNEL study – n=7/6 (vehicle/BGJ-398)].
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